Insulet Corporation (NASDAQ:PODD) Receives Average Rating of “Hold” from Brokerages

Shares of Insulet Corporation (NASDAQ:PODD) have earned an average rating of “Hold” from the twenty-seven research firms that are currently covering the stock, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, eleven have given a hold recommendation and fourteen have issued a buy recommendation on the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $195.40.

A number of research analysts recently weighed in on the stock. Benchmark lowered their target price on shares of Insulet from $250.00 to $185.00 and set a “buy” rating on the stock in a research note on Thursday, August 6th. BTIG Research lowered Insulet from a “buy” rating to a “neutral” rating in a research note on Thursday, August 6th. UBS Group lowered their price objective on Insulet from $174.00 to $150.00 and set a “neutral” rating on the stock in a research report on Thursday, August 6th. Canaccord Genuity Group dropped their price objective on Insulet from $249.00 to $179.00 and set a “buy” rating for the company in a research note on Thursday, August 6th. Finally, Deutsche Bank Aktiengesellschaft began coverage on Insulet in a research report on Tuesday, June 23rd. They set a “buy” rating and a $190.00 target price for the company.

Institutional Investors Weigh In On Insulet

Institutional investors have recently added to or reduced their stakes in the stock. Parkside Financial Bank & Trust lifted its holdings in shares of Insulet by 127.6% in the second quarter. Parkside Financial Bank & Trust now owns 528 shares of the medical instruments supplier’s stock worth $80,000 after buying an additional 296 shares in the last quarter. Corient Private Wealth LP boosted its position in shares of Insulet by 24.6% during the second quarter. Corient Private Wealth LP now owns 84,673 shares of the medical instruments supplier’s stock worth $12,891,000 after acquiring an additional 16,690 shares during the last quarter. Amundi grew its stake in Insulet by 13.6% during the second quarter. Amundi now owns 507,847 shares of the medical instruments supplier’s stock valued at $77,320,000 after acquiring an additional 60,929 shares in the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in Insulet in the 2nd quarter valued at $1,577,000. Finally, Vancity Investment Management Ltd increased its holdings in Insulet by 34.6% in the 2nd quarter. Vancity Investment Management Ltd now owns 2,866 shares of the medical instruments supplier’s stock valued at $436,000 after acquiring an additional 737 shares during the last quarter.

Insulet Price Performance

NASDAQ PODD opened at $147.48 on Friday. The company has a current ratio of 2.48, a quick ratio of 1.83 and a debt-to-equity ratio of 0.65. Insulet has a 12 month low of $126.40 and a 12 month high of $354.88. The stock has a market cap of $10.23 billion, a price-to-earnings ratio of 27.57, a PEG ratio of 1.19 and a beta of 1.08. The company’s 50 day moving average is $154.45 and its two-hundred day moving average is $177.72.

Insulet (NASDAQ:PODD) last posted its quarterly earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 earnings per share for the quarter, topping analysts’ consensus estimates of $1.47 by $0.19. The business had revenue of $801.70 million during the quarter, compared to analyst estimates of $787.39 million. Insulet had a net margin of 12.29% and a return on equity of 29.29%. The company’s revenue was up 23.5% on a year-over-year basis. During the same period in the prior year, the business posted $1.17 earnings per share. Insulet has set its FY 2026 guidance at 6.460- EPS. As a group, research analysts anticipate that Insulet will post 6.51 earnings per share for the current year.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.